The idea is that each gets some of what it needs. Payers gain some control over cost, and pharma may get to stay on formulary.
But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?
The AMA votes in favor of value-based drug pricing; Amgen says insurers are balking at PCSK9 inhibitor prices; docs aren't focused on prices when prescribing
Gilead CEO talks drug pricing; multiple-sclerosis drugmakers study the overall cost of care; Biden launches national cancer database
Cigna signs value contracts for new cholesterol drugs; Yelp partners with ProPublica for hospital reviews; ad-blocking threat to digital publishers intensifies
The formula's pretty simple: Be sure you can defend your drug's value proposition, without blushing, says BioPharma Alliance's Mike Luby.
Experts say Afrezza's tepid launch may have more to do with value proposition than product positioning.
- Five things for pharma marketers to know: Wednesday, March 22, 2017
- Drugmakers target severe asthma patients with biologics, but payers raise pricing issue
- Novartis aims to bring first oral asthma drug to market in two decades
- Veeva and QuintilesIMS tussle over customer reference data
- What five different pharma marketing careers look like
- 2017 Healthcare Marketers Trend Report: All the data in one place
- Infographic: What's next for the point of care market
- Drugmakers again boost DTC spending, to $5.6 billion in 2016
- Digital IDs become focus as drugmakers seek to track doctors' behavior online
- Some CME experts remain skeptical when it comes to social media